secwatch.observer — SEC 8-K summary
======================================

Issuer:     Taysha Gene Therapies, Inc. (TSHA)
CIK:        0001806310
Form:       8-K
Filed at:   2023-12-20T23:59:59+00:00
Accession:  0001193125-23-299942
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Taysha grants ~5.3M options and RSUs to top executives; adopts 4M-share inducement plan
--------------------------------------------------------------------------------

- CEO Sean Nolan receives 1,184,688 options and 1,184,688 RSUs (total ~2.37M shares).
- President & Head of R&D Sukumar Nagendran receives 863,617 options and 863,617 RSUs.
- CFO Kamran Alam receives 590,413 options and 590,413 RSUs.
- Options vest 25% at 1 year, then monthly over 3 years; RSUs vest equally over 4 years.
- Board adopted 2023 Inducement Plan reserving 4M shares for new-hire grants under Nasdaq Rule 5635(c)(4).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523299942/0001193125-23-299942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806310/000119312523299942/d574908d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-299942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer